Tocilizumab Approved for the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease
The FDA has approved Actemra® (tocilizumab; Genentech) subcutaneous injection for slowing the rate of decline in pulmonary function in SSc-ILD.
The FDA has approved Actemra® (tocilizumab; Genentech) subcutaneous injection for slowing the rate of decline in pulmonary function in SSc-ILD.
Belimumab is already indicated for the treatment of active, autoantibody-positive systemic lupus erythematosus in individuals aged 5 years and over.
The NIAID has launched a new study aimed at accelerating the most promising therapies in the fight against coronavirus disease 2019.
The US Department of Health and Human Services and the Department of Defense have agreed to receive 100 million doses of BNT162, a vaccine for SARS-CoV-2, once the manufacturers obtains approval or emergency use authorization (EUA) from the FDA
Haymarket Medical Network, a part of business media company Haymarket Media, Inc., is proud to join the Ad Council’s first ever Private Marketplace (PMP) along with other partners Cadreon, The Trade Desk and Acxiom.
The FDA Advil Dual Action with Acetaminophen for the temporary relief of minor aches and pains due to arthritis and more.
Dr. Reddy’s Laboratories announced the launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets, the generic equivalent to Vimovo®.
The over-the-counter (OTC), drug-free medical device, ActiPatch®, has obtained a new 510(k) clearance from the Food and Drug Administration (FDA) for the adjunctive treatment of musculoskeletal pain.
Caroline O. Pardo, Ph.D., General Manager for Haymarket Medical Education, is pleased to announce that HME, based in Paramus, NJ, has been accredited as a provider of interprofessional continuing education by the Accreditation Council for Continuing Medical Education, the Accreditation Council for Pharmacy Education, and the American Nursing Credentialing Center.
The Company is currently conducting a comparative study with the aim of having the treatment designated as a therapeutic equivalent to Forteo.